Pharmaceutical Technology

DECEMBER 20, 2023

The EC has revoked marketing authorisations for Tecfidera generics, granting the drug marketing protection until February 2025.

Marketing 52

Marketing 52

Fierce Pharma

APRIL 30, 2024

While an ongoing production expansion push for Eli Lilly's popular tirezeptide-based medicines Mounjaro and Zepbound should help out with perpetual supply strains later this year, the expected | While Eli Lilly's supply for Mounjaro and Zepbound is scheduled to increase during the second half of the year, demand is still expected to outpace (..)

Medicine 240

Medicine 240

pharmaphorum

AUGUST 24, 2022

The biotech has confirmed it will not launch the biosimilar until March 2025 however, honouring the terms of its 2020 agreement with Alexion that resolved litigation over the validity of patents covering Soliris (eculizumab) in the US.

Safety 85

Safety Sales Patients FDA 85

Fierce Pharma

MARCH 21, 2024

The drugmaker's commitment will start by January 1, 2025, and follows similar moves by peers Boehringer Ingelheim and AstraZeneca. Amid congressional scrutiny on U.S. | Before the pledges, the companies—and Teva—caught Senate heat over high U.S. inhaler prices.

247

247

Fierce Pharma

JUNE 12, 2023

market without a patent infringement challenge by early 2025 thanks to a new settlement. 21, 2025. Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb.

Marketing 273

Marketing 273

Fierce Pharma

AUGUST 23, 2023

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix.

214

214

Fierce Pharma

NOVEMBER 1, 2023

But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit. The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. |

FDA 254

FDA 254

Prognos Health

NOVEMBER 18, 2021

Prognos CEO Sundeep Bhan was a featured panelist in a session titled The Data Ecosystem in 2025 , which also included leaders from CVS Health, Komodo Health, and Blue Health Intelligence Ⓡ (BHI Ⓡ ). ” The post Highlights from The Data Ecosystem in 2025 appeared first on Prognos Health.

Healthcare 52

Healthcare Healthcare Patients Healthcare Provider 52

Fierce Pharma

SEPTEMBER 11, 2023

Versions from Amgen, Teva and Alvotech are expected to launch in early 2025. . | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.

Marketing 256

Marketing 256

Fierce Pharma

OCTOBER 24, 2023

The company expects a decision in the first quarter of next year and is making plans to launch the treatment in the 2024-2025 flu season. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent.

FDA 254

FDA Marketing 254

Fierce Pharma

JUNE 29, 2023

Much of that momentum hinges on Sanofi’s pipeline, where the company is targeting an “accelerated pace of innovation” in a bid to launch at least five phase 3 vaccine programs by 2025.

Sales 220

Sales 220

MedCity News

APRIL 2, 2024

America’s Health Insurance Plans, the Better Medicare Alliance and the Association for Community Affiliated Plans all came out against CMS’ final 2025 Medicare Advantage and Part D rate announcement. The post Insurer Advocacy Orgs Slam Final MA, Part D Rate Announcement appeared first on MedCity News.

Insurance 114

Insurance 114

MedCity News

APRIL 18, 2024

Included Health’s new specialty care clinic, which will become available in 2025, is starting by offering three centers: the Cancer Center, the Center for Women’s Health and the Center for Metabolic Health. The post Included Health Announces New Specialty Care Offering appeared first on MedCity News.

102

102

MedCity News

APRIL 22, 2024

In 2025, the task force will release a blueprint of actionable recommendations on how employers can improve their coverage. The Commonwealth Fund recently launched the National Task Force on the Future Role of Employers in the U.S. Health System.

Insurance 100

Insurance 100

Fierce Pharma

JULY 10, 2023

After a Delaware federal court ruled a Novartis combination patent on big-selling cardiovascular drug Entresto is invalid, the company pledged to continue its efforts to block generics with an appe | After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S.

199

199

Fierce Pharma

NOVEMBER 30, 2023

22, 2025, pending an FDA approval. As Johnson & Johnson’s top moneymaker Stelara nears its patent cliff, biosimilar makers are eager to launch their own versions of the blockbuster immunology med. Samsung Bioepis' biosimilar, which Sandoz has agreed to commercialize, can launch on Feb.

FDA 130

FDA Marketing 130

pharmaphorum

APRIL 23, 2024

BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third quarter of 2025.

76

76

PharmaTech

APRIL 30, 2024

Key areas to invest include manufacturing process improvements, quality management, and AI.

Manufacturing 64

Manufacturing Management 64

Pharmaceutical Technology

NOVEMBER 22, 2023

The funding will go towards the development of the company's four CNS candidates, with Phase II study data readouts expected by early 2025.

116

116

Fierce Pharma

JUNE 30, 2023

billion) from its Bio CDMO business by March 2025. Fujifilm has tapped a new leader on its quest to deliver 200 billion yen ($1.4 Effective immediately, company veteran Lars Petersen has ascended to the throne as president and chief executive officer of Fujifilm Diosynth Biotechnologies.

130

130

Prognos Health

NOVEMBER 18, 2021

Datavant , the leader in helping healthcare organizations securely connect their data and a Prognos Health partner, recently held its Future of Health Data Summit in Washington DC. This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes.

Healthcare 52

Healthcare Healthcare Patients 52

MedCity News

JANUARY 15, 2024

Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates. Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy.

Medicine 95

Medicine Healthcare Healthcare Biopharma 95

MedCity News

MARCH 11, 2024

Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025. Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders.

Biopharma 70

Biopharma Pharma 70

Pharmaceutical Technology

OCTOBER 2, 2023

An NDA submission for EryDex is currently intended for Q4 2025, assuming positive Phase III study results.

FDA 105

FDA 105

Pharmaceutical Technology

APRIL 8, 2024

Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.

Leads 52

Leads 52

MedCity News

DECEMBER 19, 2023

Both partners expect to complete the product’s FDA submission by 2025.

Networking 114

Networking FDA 114

Pharmaceutical Technology

JANUARY 8, 2024

The layoffs and scaling back of R&D activities will extend Senti Biosciences' cash runway into Q1 2025, according to a press release.

64

64

MedCity News

JANUARY 16, 2023

A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.

Patients 115

Patients 115

Pharmaceutical Technology

FEBRUARY 15, 2024

In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.

Marketing 52

Marketing 52

MedCity News

JULY 24, 2023

Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025. In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5%

Patients 82

Patients FDA Biopharma 82

Pharmaceutical Commerce

JUNE 2, 2023

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Patients 98

Patients 98

Pharmaceutical Technology

JULY 20, 2023

Ahead of APEC’s "Rare disease vision 2025" deadline, Asian countries are working at different speeds towards improving drug market access.

Marketing 75

Marketing 75

European Pharmaceutical Review

JANUARY 31, 2023

A new strategy for 2023-2025 by the Medicines Patent Pool (MPP) aims to reduce access inequities, by improving the availability and affordability of health products in low- and middle-income countries (LMICs). Part of the plan includes enabling 30 million people to access MPP-licensed products each year by 2025.

Medicine 91

Medicine Manufacturing Healthcare Healthcare 91

European Pharmaceutical Review

MARCH 24, 2023

The European Medicines Agency (EMA) has published a report summarising the mid-point achievements of its Regulatory Science Strategy (RSS) to 2025. Initially published in March 2020, the strategy provides a plan for advancing regulatory science over a five-year period.

Medicine 76

Medicine Consulting Networking Safety 76

MedCity News

DECEMBER 6, 2022

Given that providers are under increased pressure from CMS to take on some form of downside risk by 2025, they and health plans can utilize these four strategies to make the transition smoother.

Physicians 82

Physicians 82

Pharmaceutical Technology

OCTOBER 31, 2023

The laboratory will be operational by Q3 2024, and the first manufacturing suite is expected to be operational in Q3 2025.

Manufacturing 59

Manufacturing 59

Pharmaceutical Technology

NOVEMBER 3, 2023

The large amendment to Poland’s Reimbursement Act (Duża Nowelizacja Ustawy Refundacyjnej, DNUR) finally came into legal force on November 1, although a small number of its regulations will only come into force in 2024 and 2025.

Marketing 52

Marketing 52